Guideline Updates

The National Comprehensive Cancer Network issued updated guidelines for prostate cancer, including new information about the role of family history, specific mutations, and microsatellite instability testing.
The National Comprehensive Cancer Network released updated guidelines for a variety of B-cell lymphomas, including follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and diffuse large B-cell lymphoma.
The American Society of Clinical Oncology and the National Comprehensive Cancer Network have collaborated for the first time to release new clinical guidelines for managing immunotherapy-related toxicities.
The National Comprehensive Cancer Network updated their induction and consolidation treatment recommendations for low-risk and high-risk acute myeloid leukemia.
The National Comprehensive Cancer Network has updated their guideline for breast cancer risk reduction, including significant changes to the section on components of risk/benefit assessment and counseling.
The National Comprehensive Cancer Network revised their criteria for discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
The National Comprehensive Cancer Network modified their guidelines for both non-small cell lung cancer and lung cancer screening to reflect new staging designations and testing results.
The American Society of Clinical Oncology released a clinical practice guideline update on the role of bone-modifying agents in patients with active symptomatic multiple myeloma.
The National Comprehensive Cancer Network recently made similar treatment and management changes for their colon and rectal cancer guidelines.
The National Comprehensive Cancer Network released new additions to their guidelines for bladder cancer, including changes to systemic therapy, primary treatments, and adjuvant treatments.